INDVIndivior Pharmaceuticals, Inc.
Is the business good?
The checks split: nothing decisive, though profits without cash flow.
Mixed fundamental signals. Nine pass/fail tests of year-over-year health from the filings.
Reports an operating profit but operating cash flow is negative, a red flag. Conversion is worsening vs a year ago.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. The F-score rewards improvement, so an already-elite company can score mid-pack.
How good a business is INDV?
Indivior Pharmaceuticals, Inc. keeps 32% of every revenue dollar as operating profit, against 11% for the median Drug Manufacturers - Specialty & Generic name.
Operating margin · Drug Manufacturers - Specialty & Generic median 11% · 12 months to Q2 2026
- Cash conversion
- −0.10×
Cash conversion · 1.73× a year ago · the operating profit has not turned into cash yet
- Share count, year on year
- −1.6%
Share count, year on year · bought back, each share owns more of the company
- R&D as % of revenue
- 6.2%
R&D as % of revenue
| Year | Operating margin |
|---|---|
| FY2022 | −9.0% |
| FY2023 | −14% |
| FY2024 | 3.2% |
| FY2025 | 21% |
Details›
- Gross margin12 months to Q2 2026
- 82%
- Operating margin12 months to Q2 2026
- 32%
- Net margin12 months to Q2 2026
- 27%
- Free cash flow margin
- −8.3%
- R&D as % of revenue
- 6.2%
- Revenue, trailing twelve months
- $1.33B
- Free cash flow, trailing twelve months
- −$111M
- Net income, trailing twelve months
- $355M
Margins, capital and share counts from the statements as filed with the SEC; cash conversion is operating cash flow over operating profit after tax.
Drug Manufacturers, Specialty & Generic
Ranks #1 of 41 by RyuScore